Novel Applications of 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol Compounds in Veterinary Medicine
Legal Citation
Summary of the Inventive Concept
This inventive concept explores the use of 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds in novel veterinary applications, leveraging their CDK inhibitory properties to address unmet needs in animal health.
Background and Problem Solved
The original patent disclosed 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors for human cancer treatment. However, there is a significant need for effective treatments for neurological disorders, anxiety, and cognitive decline in companion animals. This inventive concept addresses these unmet needs by applying the core technology to veterinary medicine.
Detailed Description of the Inventive Concept
The new claims describe systems, methods, and compositions for treating neurological disorders, reducing anxiety, and improving cognitive function in animals using 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds. These inventions encompass various delivery mechanisms, nutritional supplements, and diagnostic tools tailored to the specific needs of veterinary medicine.
Novelty and Inventive Step
The novelty of this inventive concept lies in the unexpected application of 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds to veterinary medicine, which is not obvious from the original patent's focus on human cancer treatment.
Alternative Embodiments and Variations
Alternative embodiments may include different formulations, dosing regimens, and administration routes for the compounds, as well as integration with existing veterinary diagnostic tools and treatments.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the veterinary pharmaceutical industry, with a growing market demand for effective treatments for animal health and wellness.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical chemistry, specifically medicinal chemistry focused on CDK inhibitors and neurological disorder treatments across human and veterinary medical applications
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degree in pharmaceutical sciences, expertise in drug repurposing, neurological disorder treatments, and translational research methodologies with knowledge of CDK inhibitor mechanisms
Obviousness Rationale
A PHOSITA would recognize that the core 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compound's therapeutic potential extends beyond human cancer treatment to veterinary neurological applications. The molecular mechanism of CDK inhibition is fundamentally similar across mammalian species, making translational research a predictable scientific approach. The PTD's veterinary applications represent a logical extension of the source patent's foundational chemical and pharmacological research.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,552 |
|---|---|
| Title | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors |
| Assignee(s) | CARRICK THERAPEUTICS LIMITED |